Home > Riviste > Minerva Obstetrics and Gynecology > Fascicoli precedenti > Minerva Obstetrics and Gynecology 2022 December;74(6) > Minerva Obstetrics and Gynecology 2022 December;74(6):516-21



Opzioni di pubblicazione
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca


Publication history
Per citare questo articolo



Minerva Obstetrics and Gynecology 2022 December;74(6):516-21

DOI: 10.23736/S2724-606X.21.04964-2


lingua: Inglese

The benefits of purified cytoplasm of pollen in reducing menopausal symptoms in peri- and post-menopause: an Italian multicenter prospective observational study

Stefano LELLO 1, 2, Anna CAPOZZI 1, 2 , Anjeza XHOLLI 3, Angelo CAGNACCI 3, on behalf of Italian Society of Menopause (SIM), the Italian Society of Gynecology of the Third Age of Women (SIGiTE), and the Pollen Extract in Menopause Italian Study Group 

1 Istituto Dermopatico dell’Immacolata - IRCCS, Rome, Italy; 2 Department of Maternal and Child Health, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy; 3 Clinic of Obstetrics and Gynecology, IRCCS San Martino University Hospital, Genoa, Italy; 3 Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, and Maternal and Child Health, IRCCS San Martino University Hospital, Genoa, Italy

BACKGROUND: Purified cytoplasm of pollen (PCP) is a non-hormonal herbal remedy used to manage vasomotor symptoms (VMS), sleep and mood disorders in menopausal women not relying on Hormone Replacement Therapy (HRT). Many studies demonstrated its efficacy and safety in post-menopause but few data are available about peri-menopause.
METHODS: This is a multicenter prospective observational study on Italian symptomatic women in peri- and post-menopause referring to gynecology clinics of different areas of Italy, evaluating the effects of PCP therapy on hot flashes (HFs) and other parameters included in the Greene Climacteric Scale (GCS).
RESULTS: We recruited 108 peri- and post-menopausal women (mean age 53.8±4 years), evaluating them at baseline (V0) and after 3 months of PCP treatment (V1). Basal median value of all items of GCS did not differ among all subjects. We found a significant improvement of HFs (P<0.0001) and night sweats (P<0.0001) between V0 and V1. Additionally, all items of GCS apart from loss of sensitivity to limbs (P=0.0746) significantly ameliorated after PCP therapy (P<0.05).
CONCLUSIONS: According to these findings, PCP may be considered as an efficacious alternative non-hormonal treatment for the management of VMS as well as mood and sleep disturbances in both peri- and post-menopause.

KEY WORDS: Cytoplasm; Pollen; Perimenopause; Hot flashes; Mood disorders; Sleep wake disorders

inizio pagina